dipeptidyl peptidase-4 inhibitors

Overview

Dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors, also termed DPP-4is or gliptins) are a class of oral antihyperglycemic agents widely used in the management of type 2 diabetes mellitus (T2DM). They act by blocking the enzyme dipeptidyl peptidase-4, which is responsible for the rapid degradation of incretin hormones, most notably glucagon-like peptide-1 (GLP-1) (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By inhibiting DPP-4, these drugs prolong the activity of endogenous incretins, thereby enhancing glucose-dependent insulin secretion, suppressing glucagon release, and improving overall glycemic control with a relatively low risk of hypoglycemia. Commonly used agents in this class include sitagliptin, saxagliptin, alogliptin, linagliptin, and vildagliptin. DPP-4 inhibitors are generally well tolerated, weight-neutral, and suitable for use across a broad range of patients, including older adults and those with renal impairment at adjusted doses.

Beyond their primary glucose-lowering role, DPP-4 inhibitors have attracted significant scientific interest for their potential pleiotropic effects on hepatic, renal, cardiovascular, and neurological systems. As the therapeutic landscape for type 2 diabetes has expanded—with newer agents such as glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs) and sodium glucose cotransporter-2 (SGLT2) inhibitors (SGLT2 inhibitors) demonstrating cardiometabolic and organ-protective benefits—DPP-4 inhibitors have increasingly been used as active comparators in head-to-head clinical and real-world studies. This positioning reflects their established safety profile and widespread clinical use, making them a natural reference class for evaluating the incremental benefits of emerging diabetes therapies.

Recent Publications Summary

Recent publications on dipeptidyl peptidase-4 inhibitors (DPP-4i) have focused largely on comparative real-world effectiveness and safety in type 2 diabetes, often using DPP-4i as the reference treatment. In a nationwide propensity-matched study from Korea, empagliflozin was compared with DPP-4i in adults who maintained therapy for more than 365 days; empagliflozin was associated with lower risks of all-cause hospitalization and kidney events versus DPP-4i, while acute safety outcomes were assessed only exploratorily because the sustained-exposure design may underrepresent early events 42342812Jun. Other recent comparative studies similarly used DPP-4i as the comparator for glucagon-like peptide-1 receptor agonists, including analyses of hepatic decompensation, femur fracture risk, and all-cause mortality in people with type 2 diabetes 41847743Mar41819195Mar41741950Feb.

safety-focused work has also examined potential adverse events associated with DPP-4i themselves. A disproportionality analysis based on the FAERS database evaluated whether DPP-4i use was associated with acute kidney injury in patients with diabetes, explicitly considering concomitant use of other acute kidney injury-inducing drugs, although the abstract does not provide the study’s numerical findings 42049410Apr. In addition, a real-world study from India was designed to assess urinary tract and genital tract infections with sodium-glucose cotransporter-2 inhibitors alone or in combination with DPP-4i in individuals with type 2 diabetes, reflecting ongoing interest in infection risk with combination therapy 42163184May.

Beyond comparative effectiveness and safety, DPP-4i have also been investigated for potential neuroprotective applications. A proteomics, target prediction, and molecular docking study explored repurposing DPP-4i, together with metformin, for mild cognitive impairment in type 2 diabetes, aiming to clarify mechanisms underlying possible neuroprotection 41587770Jan. Overall, the recent literature positions DPP-4i primarily as a comparator in head-to-head diabetes treatment studies, while also continuing to evaluate their own safety profile and possible roles in complications beyond glycemic control 42342812Jun42049410Apr41587770Jan.

What Changes, What Holds

1. DPP-4 inhibitors are now mainly serving as the reference arm in comparative effectiveness studies
NEW DIRECTION Recent work does not revise the glucose-lowering mechanism or core clinical role described in the Overview; instead, it shows the class is increasingly being used as the benchmark against which newer diabetes drugs are judged. That shifts their research significance from “active therapy” to “standard comparator,” especially in real-world studies where downstream hospitalization, kidney, hepatic, fracture, and mortality outcomes are being contrasted with DPP-4i use 42342812Jun41847743Mar.

2. safety signals remain unsettled, but the class is still being scrutinized for kidney and infection risks
NEW DIRECTION The new studies do not overturn the established view that DPP-4 inhibitors are generally well tolerated, but they do extend the safety conversation into specific adverse-event questions that the Overview does not settle. A pharmacovigilance signal for acute kidney injury and a combination-therapy infection analysis suggest ongoing uncertainty about rare harms, especially in patients exposed to other risk-modifying drugs 42049410Apr42163184May.

3. DPP-4 inhibitors are being explored beyond glycemic control as candidates for neuroprotective repurposing
NEW DIRECTION This work adds a non-diabetes complication role that the Overview does not cover: possible use in mild cognitive impairment in people with type 2 diabetes. It does not contradict the established antihyperglycemic account, but it does broaden the class’s perceived therapeutic horizon from glucose control and organ-protection hypotheses to mechanistic repurposing for cognitive outcomes, albeit on early, hypothesis-generating evidence 41587770Jan.

Overview update candidates: DPP-4 inhibitors are increasingly used as comparator drugs in head-to-head diabetes outcome studies; safety questions about acute kidney injury and infection risk remain under active investigation; exploratory repurposing for cognitive impairment in type 2 diabetes is a new direction but not yet established enough for the Overview.